{"filing":{"accession_number":"0001193125-26-277639","cik":"0001593899","ticker":"AVIR","company_name":"Atea Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d11075d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1593899/000119312526277639/d11075d8k.htm"},"events":[{"id":12846,"run_id":11399,"accession_number":"0001193125-26-277639","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure reports the final voting results from Atea Pharmaceuticals' June 18, 2026 Annual Meeting of Stockholders, including the election of three Class III directors (Jerome Adams, Howard Berman, and Barbara Duncan), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents certified vote tallies for each proposal and confirms their passage, which is the core purpose of Item 5.07 shareholder vote results disclosures.","company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9812,"accession_number":"0001193125-26-277639","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from Atea Pharmaceuticals' June 18, 2026 Annual Meeting of Stockholders, including the election of three Class III directors (Jerome Adams, Howard Berman, and Barbara Duncan), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents certified vote tallies for each proposal and confirms their passage, which is the core purpose of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:32:46.979091+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9812,"accession_number":"0001193125-26-277639","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from Atea Pharmaceuticals' June 18, 2026 Annual Meeting of Stockholders, including the election of three Class III directors (Jerome Adams, Howard Berman, and Barbara Duncan), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents certified vote tallies for each proposal and confirms their passage, which is the core purpose of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:32:46.979091+00:00","company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","filing_date":"2026-06-22"}]}